Why Summit Therapeutics Skyrocketed 123% This Week
WEBSep 13, 2024 · Shares of Summit Therapeutics (SMMT 5.31%) rocketed 123.4% higher this week through Thursday trading, according to data from S&P Global Market Intelligence.
Summit a ‘top pick’ at Citi after ‘unprecedented’ trial results, bull ...
WEBSep 9, 2024 · Citi promoted Summit Therapeutics (NASDAQ: SMMT) as a top pick in a new note following the latest clinical trial data on its investigational bispecific antibody, ivonescimab. The new data also...
Why Summit Therapeutics Rocketed Over 60% Today - Yahoo …
WEBSep 9, 2024 · Shares of Summit Therapeutics (NASDAQ: SMMT) rocketed as high as 75.2% Monday, before settling into a 57.5% gain as of 1:27 PM EDT. The biotech firm released the results of a Phase III study on ...
Summit shares hit record high as cancer drug tops Keytruda in …
WEBSept 9 (Reuters) - Summit Therapeutics (SMMT.O) shares soared as much as 75% to a record high on Monday as a study in China showed some lung cancer patients on the company's experimental drug...
Press Releases - Summit Therapeutics
WEBFeb 20, 2024 · Summit Therapeutics Announces Timing of Rights Offering for Up to $500 Million. January 20, 2023. Summit Therapeutics Closes Deal with Akeso Inc. to In-License Breakthrough Innovative Bispecific Antibody. January 5, 2023. Summit Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference.
Summit Therapeutics Announces Updated Phase II Data for …
WEBJan 8, 2024 · Phase II mOS of 22.5 Months in 2L+ EGFRm, TKI-progressed NSCLC Patients. Catalyst Events Expected in Q2 2024 for Two Randomized Phase III Trials Evaluating Ivonescimab in China Conducted by Akeso...
Summit Therapeutics Inc. (SMMT) Stock Price, News, Quote
WEBFind the latest Summit Therapeutics Inc. (SMMT) stock quote, history, news and other vital information to help you with your stock trading and investing.
Summit Therapeutics Surges on Trial Results: Time to Buy?
WEBSep 12, 2024 · Getting to Know Summit Therapeutics. Summit Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative therapies across the U.S. and U.K. Its lead candidate ...
Summit Therapeutics Reports Financial Results and Operational …
WEBMay 1, 2024 · Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024. HARMONi and HARMONi-3 Enrollment Continues. Promising Intracranial Anti-Tumor...
Summit Therapeutics Secures $235 Million in Funding from …
WEBSep 12, 2024 · Summit Therapeutics Inc. (SMMT) is making waves today with a major announcement that has sent its stock price soaring 20.77% to $27.42 as of 12:48 PM EDT. The company has successfully raised a substantial $235 million in a private placement, attracting significant interest from both institutional …